Dulaglutide, Trulicity, has received a new FDA indication for prevention of primary (person has no established heart disease, or history of heart attack or stroke) AND secondary (person has established heart disease, or history of heart attack or stroke) reduction of major adverse cardiovascular (heart) events (i.e. heart attack or stroke) in adults with type 2 diabetes. Adults with type 2 diabetes have an elevated risk for heart attacks and strokes so proactive prevention is vital. What makes this new indication particularly important is that it is for prevention in person with or without established heart disease.
Please share your thoughts and subscribe to receive my blogs.
#Dulaglutide #primary #secondary #prevention #heart
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.